Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

J&J pays $250 million for Arrowhead Pharmaceuticals RNAi hepatitis B drug

by Ryan Cross
October 12, 2018 | A version of this story appeared in Volume 96, Issue 41

 

Johnson & Johnson is tapping Arrowhead Pharmaceuticals to license its experimental RNA interference (RNAi) therapy for the hepatitis B virus. Arrowhead will receive a $75 million equity investment and $175 million up front from J&J, and depending on how the RNAi therapy performs—currently in a Phase I/II study—Arrowhead could earn up to $1.6 billion in milestone payments. Finally, J&J may work with Arrowhead to develop three more RNAi therapies against additional targets, with $1.9 billion in potential milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.